Next-Generation Vaccine Platform Technology Company VitriVax Joins BioMed Realty’s Roster of Innovative Tenants at Flatiron Park in Boulder, Colorado

BOULDER, Colorado - March 24, 2026 - BioMed Realty, the largest private owner and operator of real estate for the life science, technology and innovation industries, announced VitriVax, a vaccine platform technology company, has leased 31,465 square feet at 5500 Central Avenue within Flatiron Park, BioMed Realty's premier Boulder campus featuring over 1 million square feet of research and development and innovation office space.

5500 Central provides adaptable infrastructure designed to support companies as they scale research and development. Situated near leading universities and surrounded by a vibrant ecosystem of life science and innovative companies within the park, tenants benefit from access to a strong research community and deep talent pipelines that support long-term growth and success.

As a BioMed Realty tenant, VitriVax also benefits from the Discover Here™ tenant exclusive program, which is designed to create an environment that energizes teams, supports company culture, and gives tenants an edge in attracting top-tier talent. The Flatiron Park experience will be further elevated with the opening of BioMed Realty's amenity center, East & Co., in Spring 2026.

VitriVax will use the space in 5500 Central to support the continued advancement of its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform. The technology is designed to enable thermostable, single-shot vaccine formulations by eliminating cold-chain storage requirements while maintaining or potentially enhancing immune response. By simplifying vaccine distribution and dosing schedules, the platform has the potential to improve access to lifesaving immunizations worldwide.

"We're excited to welcome VitriVax to the growing community of innovators at Flatiron Park," said Jon Bergschneider, President, West Coast Markets at BioMed Realty. "VitriVax's commitment to advancing human health aligns perfectly with the collaborative environment we've built here and we look forward to supporting them as they continue to scale."

"Remaining in Boulder was a deliberate decision for VitriVax," said Kimberly Erickson, VP of Operations of VitriVax. "Our scientific roots are closely tied to the University of Colorado, and proximity to CU's research community, talent pipeline, and collaborative ecosystem remains strategically important as we scale. Flatiron Park allows us to expand without leaving the community that helped build us. We also value BioMed Realty's commitment to cultivating a strong life science campus environment, and we see this as more than a lease. It's a long-term partnership within a shared innovation ecosystem."

"Also, we are looking forward to the opening of East & Co., the new amenities center under construction, which will further enhance collaboration, connection, and community within Flatiron Park."

About BioMed Realty

BioMed Realty is the leading provider of real estate solutions for the life science, technology and innovation industries. The company owns and operates 17 million square feet of purpose-built lab and office space across the world's top innovation hubs, including Boston/Cambridge, San Francisco, San Diego, Seattle, Boulder, and Cambridge, U.K. With an additional 1.5 million square feet of Class A properties under development, BioMed delivers flexible, reliable, and sustainable environments designed to accelerate discovery and keep world-changing work moving. Backed by more than 20 years of experience, BioMed Realty provides the confidence and partnership that fuel life-enhancing and world-changing innovation.

About VitriVax

VitriVax, headquartered in Boulder, Colorado, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines or therapeutics. ALTA® can be applied to a wide variety of antigens and adjuvants to protect against thermal and chemical degradation, enabling controlled release and incorporating prime doses and additional booster doses in a single-shot administration. VitriVax partners with leading pharmaceutical and biotechnology companies to integrate ALTA® into new and existing products, positioning the platform as both a next-generation vaccine solution and an alternative delivery technology for therapeutics. To learn more, visit https://vitrivaxbio.com.